Regenerative medicine in rheumatic disease-progress in tissue engineering.
Joint destruction occurs in both osteoarthritis and rheumatoid arthritis. Even in the era of biologic agents, this destruction can be delayed but not averted. As cartilage has limited ability to self-regenerate, joint arthroplasty is required. Here, we outline current tissue engineering procedures (including autologous chondrocyte implantation and in situ mesenchymal stem cell recruitment) that are routinely applied for the regenerative treatment of injured or early osteoarthritic cartilage. Potential future regenerative therapies, including administration of multipotent or pluripotent stem cells, are also discussed. In the future, cell-free, material-based (for cartilage lesions) or cell-free, factor-based (for osteoarthritic cartilage) therapies to facilitate the recruitment of repair cells and improve cartilage metabolism are likely to become more important. Moreover, delivery of anti-inflammatory factors or immunomodulatory cells could be a regenerative treatment option for rheumatoid arthritis. Tissue engineering faces a crucial phase to translate products into clinical routine and the regulatory framework for cell-based products in particular is an important issue.
Tissue Engineering Laboratory and Berlin-Brandenburg Center for Regenerative Therapies, Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany.
Jochen
J
Ringe
Gerd R
GR
Burmester
Michael
M
Sittinger
D001172:Arthritis, Rheumatoid / Q000628:therapy*; D002358:Cartilage, Articular; D019902:Chondrocytes / Q000502:physiology / Q000637:transplantation; D006801:Humans; D045164:Mesenchymal Stem Cell Transplantation; D010003:Osteoarthritis / Q000628:therapy*; D044968:Regenerative Medicine / Q000379:methods*; D023822:Tissue Engineering